Literature DB >> 29338158

Studying the Serum as Well as Serous Level of IL-17 and IL-23 in Patients with Serous Otitis Media.

Ahmad Yeghaneh Moghaddam1, Rezvan Talaei2, Hassan Nikoueinejad3, Hossein Akbari4.   

Abstract

Serous otitis media with effusion (OME) is a middle ear inflammatory response to allergens and microbes which stimulate leukocytes to produce different inflammatory mediators after obstruction of Eustachian tube. Here, we investigated the levels of these mediators, IL-17 and IL-23, in serum and middle ear fluids of children with OME. 75 patients with otitis media and 75 age and sex-matched healthy controls were enrolled in this study. IL-17 and IL-23 levels in serous secretion of the patients and their serum levels were measured in both groups by ELISA. Serum IL-17 levels were significantly higher in the patients than controls (p=0.001). There was no significant difference between serum IL-23 levels in patients and controls. Patients' serous levels of both cytokines of IL-17 and IL-23 were higher than those in serum according to different parameters of sex, age, and duration of the disease. This study shows an elevated presence of IL-17 and IL-23, as pro inflammatory cytokines, in OME. These finding may represent the contribution of such cytokines in the pathogenesis of OME. Blocking such molecules may yield new non-surgical therapeutics.

Entities:  

Keywords:  Interleukin 17; Interleukin 23; Otitis media with effusion

Mesh:

Substances:

Year:  2017        PMID: 29338158

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  2 in total

1.  Gene expression analysis reveals immune and metabolic candidate pathways in the pathogenesis of chronic otitis media.

Authors:  Siran Lin; Wei Zhang; Yuzhen Xu; Qianqian Liu; Wenhong Zhang; Lingyun Shao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  IL-17 is a Potential Therapeutic Target in a Rodent Model of Otitis Media with Effusion.

Authors:  Nanfeng Zhang; Tingting Qian; Shan Sun; Wei Cao; Zhixian Wang; Danling Liu; Peifan Li; Jingfang Wu; Huawei Li; Jianming Yang
Journal:  J Inflamm Res       Date:  2022-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.